Current experience with differential pricing of HIV/AIDS related drugs in Uganda Dorothy Ochola M.D.-Muyingo Sowedi - Malamba S. Paul J. Weidle, Pharm.D.,MPH,

Slides:



Advertisements
Similar presentations
HIV/AIDS The Epidemic in ANE and E&E So what do we do now? Paul De Lay Senior Advisor on HIV/AIDS Office of HIV/AIDS.
Advertisements

Partnerships for Health Reform Utilization and Expenditures on Outpatient Health Care by HIV Positive Individuals in Rwanda PHR Rwanda - Abt Associates.
UNDP RBA Workshop on MDG-Based National Development Strategies Module 4: Health Strategies UN Millennium Project February 27-March 3, 2006.
The Brazilian Response to AIDS Mauro Teixeira de Figueiredo Head of the Division for Technical Cooperation International Advisory Ministry of Health Main.
HIV-infection in Russia Alexander Panteleev Head of the HIV/TB department City TB Hospital # 2, St-Petersburg, Russia.
Cost-sharing for Emergency Care and Unfavorable Clinical Events: Findings from the Safety And Financial Ramifications of ED Copayments (SAFE) Study AcademyHealth.
THE COMMONWEALTH FUND Figure 1. Health Insurance Coverage and Uninsured Trends Data: Analysis of the U.S. Census Bureau, Current Population Survey Annual.
TRIPs and Public Health: The Unresolved Debate Tenu Avafia tralac
Ministry of Health National STD/AIDS Programme Universal Access to Antiretroviral Therapy: The Brazilian Experience.
Estimating and Projecting National HIV/AIDS Epidemics UNAIDS Reference Group on Estimates, Models and Projections.
How can we tailor the delivery of the TB/HIV package to IDU? David H.-U. Haerry European AIDS Treatment Group (European Community Advisory Board, Policy.
PROCURING AND DISTRIBUTING ARVs AND OTHER A.R.T COMMODITIES IN MALAWI Technical Briefing for Consultants in Procurement and Supply Management for HIV,
Group III: Demand Forecasting
Harmonization of donor reporting requirements for antiretrovirals and related drugs Presented at the WHO meeting, Geneva ( October 2005) Oteba Olowo.
First cases of AIDS identified.
Yudatiningsih I.1,Sunartono H.1,SuryawatiS.2
Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.
Cost of HIV/AIDS Adult and Pediatric Clinical Care and Treatment in Ghana Felix Asante, Jim Rosen, Futures Group/HPI August 4, 2010 Accra.
February Dakar, Senegal
World Health Organization
Introduction to Treat the Pain. The problem of unrelieved pain Globally, 7.3 million people die of cancer or HIV each year in moderate or severe pain.
Strengthening TB and HIV&AIDS Responses in East Central Uganda There is no Conflict of Interest for this presentation.
NATIONAL EVALUATION OF MEDICINES DISPENSING WITHIN BRAZILIAN AIDS PROGRAM Third International Conference for Improving Use of Medicines Azeredo TB, Luiza.
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Access to ARVs : good news bad news David Henry WHO Collaborating Centre for Rational Use of Drugs The University of Newcastle NSW.
HIV Prevention, treatment and care among people who inject drugs Fabienne Hariga, MD, MPH Senior HIV Adviser, UNODC Vienna.
AIDS/Other Diseases Sub-Saharan Africa.
Progress on implementation of Pharmacovigilance in the NATIONAL ARV PROGRAMME November 2009 Dr Mwango A National ARV Programme Coordinator, Ministry of.
Application of an International Reference Price List to National Medicines Procurement Tenders Bada Pharasi, Gavin Steel, Jean-Pierre Sallet, SPS, Management.
Kevin Fenton, MD, PhD, FFPH Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Centers for Disease Control and Prevention.
The Role of TNCs and AIDS drugs – “Lives before profits”? L.O.s 1.To define the terms: TNC, Generic, “Big Pharma”, ARVs, HAART, Tiered Pricing. 2.To describe.
TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.
Uptake of antiretrovirals in a cohort of women involved in high risk sexual behaviour in Kampala, Uganda J.Bukenya, M. Kwikiriza, O. Musana, J. Ssensamba,
HIV Therapy for the Developing World: A Global Health Challenge Harold W. Jaffe, MD Department of Public Health University of Oxford Oxford, UK.
Global Response to HIV/AIDS Nigerian Nurses Association of USA June 30, 2006 Carolyn M Hall, MSN/MPH, ACRN Global HIV/AIDS Program U.S. Department of Health.
Botswana Experience on Public- Private Partnerships Joconiah Chirenda, MD, MPH, MBA Global Business Coalition on.
PROGRAM UPDATE OVERCOMING HIV/AIDS EPIDEMICS IN UKRAINE NATIONAL PROGRAM SUPPORTED BY GFATM COMPONENT: TREATMENT, CARE AND SUPPORT Presentation by Treatment,
Funding Universal Access through a “Global Health Charge” on alcohol and tobacco: feasibility in the 20 countries with the largest HIV epidemics Dr Andrew.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
Pioneering IMAI: Developing an integrated approach in Uganda Dr Elizabeth Madraa, Program Manager National STD/AIDS Control Program MOH - UGANDA 5 th Dec.
Downloaded from Current Status of ART Opportunities & Challenges Kibrebeal Melaku,MD Associate Professor.
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
4. Access to medication & healthcare Learning objectives: - to identify the why many people cannot access medication - to understand how NGOs and the UN.
2004: 39.4 (35.9 – 44.3) million Western & Central Europe [ – ] North Africa & Middle East [ – 1.5 million] Sub-Saharan.
The National HIV Counselling and Testing Campaign and Treatment Expansion in South Africa: A return on investments in combination prevention XIX International.
PERSPECTIVES FROM THE FIELD DR LYDIA MUNGHERERA TASO (The Aids Support Organisation) UGANDA REVERSING THE TIDE OF TB.
Dr Ihor Perehinets MD, MPH National Technical Officer WHO CO in Ukraine Pharmacovigilance (PV) in HIV treatment in Ukraine: Situation Analysis Dar es Salaam.
Announcements Already fourth week! Already fourth week! Remember…four response papers (one page) and two mini essays (two pages) Remember…four response.
Paramente Phamotse (Mr.) CEO – PRIMARY MINISTRY OF EDUCATION & TRAINING, Kingdom of Lesotho HIV & AIDS and the Education Sector in Lesotho Presented on.
Universal Access: To what extent current mechanisms are appropriate and sustainable to maintain free of charge treatment? Compulsory Licensing in Brazil.
1 Scaling-up ARV Therapy in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.
What we know about the Impact of HIV/AIDS on Teachers: a general overview by Alan Whiteside and Peter Badcock- Walters Health Economics and HIV/AIDS Research.
HHS/CDC Track 1.0 Transition in Rwanda Dr Ida Kankindi, Rwanda Ministry of Health Dr Felix Kayigamba, CDC-Rwanda August
Tuberculosis and HIV-AIDS: Achievements with ARV access Dr. Humberto Costa, MD Minister of Health, Brazil.
Prevention of Mother-to-Child Transmission of HIV: Scale-up of Critical Services in Uganda (District- based Approach) Edward Bitarakwate, MD, MPH Technical.
Global Diseases: HIV/AIDS DR. Amjad Fathi El-Shanti MD,NPH,DR PH University of Palestine 2016.
Important diseases and their global impact Objectives To be able to describe the causes and means of transmission of malaria, AIDS/HIV and T.B To be able.
#AIDS2016 HOW TO LAUNCH PROGRAMMES FOR PEOPLE WHO USE SUBSTANCES AND ARE AFFECTED BY HIV ACROSS MORE GENERALIZED HIV EPIDEMIC SETTINGS.
Justine Mirembe MD, MPH ICASA, 5th December 2011
HIV and AIDS The management of HIV and AIDS is an ongoing challenge for Anglo companies operating in countries with a high burden of HIV disease Strategy.
Expanding ARV treatment in developing countries: Issues and Prospects
Global epidemiology of injecting drug use
World Health Organization
Antiretroviral therapy coverage in sub-Saharan Africa,
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies Introduction and Overview May 30 to June 4, 2005 Abuja, Nigeria.
Serge Masyn Director, Johnson & Johnson Global Public Health
China 2010 UNGASS Country Progress Report
ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: PROGRESS & CHALLENGES IN SOUTH AFRICA YOGAN PILLAY DEPARTMENT OF HEALTH, SOUTH AFRICA IAS, 2014.
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

Current experience with differential pricing of HIV/AIDS related drugs in Uganda Dorothy Ochola M.D.-Muyingo Sowedi - Malamba S. Paul J. Weidle, Pharm.D.,MPH, - Joseph Saba, MD. 10 April 2001 – Høsbjør, Norway Based on experience from UNAIDS Drug Access Initiative

Background (1) Estimated population of 21 million people (1998) Average HIV prevalence is 7%. An estimated cumulative number of 2,276,000 to have been infected since the onset of the epidemic in ,438,000 estimated to have died. GNP per capita: $310 (1998).

Background (2) HIV-related drugs in several categories –STI drugs provided to patients through STIP –Basic drugs for treatment of opportunistic infections –TB drugs –Basic drugs for pain relief & symptom control –Antiretrovirals & sophisticated drugs for opportunistic infections – patient meets full cost

The UNAIDS/MOH D.A.I. UNAIDS/MOH HIV Drug Access Initiative. Goal: to increase access to HIV-related drugs and care. Two major mechanisms: Adequate healthcare infrastructures Differential pricing and responsive distribution system

D.A.I.: Implementation Pilot Program initiated in June –Access to antiretroviral drugs initiated 1 Aug –National Advisory Board to oversee activities. –Mechanism for negotiations, procurement and distribution for ARVs established –Treatment centres for access to ARVs accredited. –Training of health providers in correct use of drugs conducted –Patients pay for ARV medications and medical visits

ARV Price Analysis - Objectives Carried out in December 2000 with the following objectives: –Describe the cost of ARV drug combinations to patients in Uganda. –Describe reasons for price fluctuations of ARV to patients in Uganda. –Quantify the price reductions as at end of 2000.

Method Information on cost of ARV gathered from medical Access (U) Ltd. –From August 1998 – December –Costs of drugs purchased in foreign currency 7 converted to Ugandan shillings Information on costs of drugs to patients gathered from treatment centres. –= cost of drug to medical access plus small mark-up

ARV price reduction in Uganda at initiation of DAI – August 1998

ARV costs in response to Currency Valuation & Price Changes Uganda,

Reasons for recent price reductions Negotiated reductions in the prices of some drugs from multinational phamaceutical manufacturers Pressure from Governments, PWAs and other activists in developed countries on multinational companies

May 2000 announcement: Further Price Reductions 5 pharmaceutical companies/5 UN Agencies pledged to substancially reduce prices for developing countries. Effected in Uganda – November-December Price reductions for individual products 0-83% compared to Feb 2000 prices. Price reduction not same for all drugs (>50% for 6 drugs, 25-50% for 2 and <5% for 6 drugs).

Cost of 30 days supply of Combinations of ARVs in Uganda Feb Dec 2000

Cost of 30 days supply of Combinations of ARVs in Uganda using Generic Vs. Brand Name Drugs - Dec 2000

CENTERSTART DATE JUL-2000DEC-2000JAN 01 *JCRC01-Aug (46%) Nsambya06-Aug (31%) Mildmay05-Oct (17%) Mulago21-Jun ( 4%) 41 Mengo02-Jan ( 1%) 12 Total * Additional 536 patients started purchasing ARVs before August 1998 or had no clinical records at the center ENROLMENT AFTER NEW PRICE REDUCTIONS

Lessons learned (1) The cost of ARVs is only one aspect of total cost of providing HIV/AIDS care. Few HIV/AIDS individuals have adequate financial resources to purchase ARVs – majority cannot afford even at current reduced costs.

Lessons learned (2) Need more public funding to enhance healthcare infrastructure and subsidize further drug costs. Depreciation of local currency may affect patients purchasing power, and therefore quality of care. Further price reductions will enable more of those previously on dual therapy to access HAART.

Conclusions Differential pricing can be looked at from two perspectives: the health care provider and the care seeker. In developing countries most care seekers cannot meet the costs. The provider to some extent is under obligation to fill the gap. We have recently seen important efforts for differential pricing. What are care providers prepared to do?